Mdd clinical trials

Explore recruiting mdd clinical trials.

Recruiting mdd studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Mdd trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

NBI-1065845-MDD3028: A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)

Bulgaria, Poland, Belgium, Croatia, Netherlands, Sweden +10 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomised, controlled trial to investigate the effect of a four/six week intensified pharmacological treatment for schizophrenia, major depressive disorder and bipolar depression compared to treatment as usual in subjects who had a first-time treatment failure on their first-line treatment.

Germany, Italy, Austria, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Reward-specific changes of cerebral dopamine synthesis in healthy volunteers and depressed patients

Austria

Therapeutic use (Phase IV) EU CTIS Study details

NBI-1065845-MDD3026: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)

Finland, Latvia, Belgium, Hungary

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Adults with Major Depressive Disorder (MDD), with or without Anxious Distress

Bulgaria, Slovakia, Czechia, Germany, Hungary, Romania +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Multi-centre, double-blind, placebo-controlled, randomised trial to prove the efficacy and safety of Silexan® (WS®1265) in patients with a major depressive episode of mild to moderate severity

Germany, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Mdd trials by city

Mdd in Toronto Mdd in Vancouver Mdd in Montreal Mdd in Calgary Mdd in Edmonton Mdd in Ottawa Mdd in Winnipeg Mdd in Quebec City Mdd in Hamilton Mdd in Kitchener Mdd in London Mdd in Halifax Mdd in New York Mdd in Los Angeles Mdd in Chicago Mdd in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease